pair_id,group_no,sent1,sent2,sent1_contradiction,sent1_neutral,sent2_contradiction,sent2_neutral
13_0,13,The ecNOS gene a/b polymorphism and the NADH/NADPH oxidase p22 phox gene C242T polymorphism were found to be significantly associated with the development of CAD in Korean male patients less than 51 years old.,"It is concluded that the C242T polymorphism of the p22 phox gene is not associated with lipid peroxidation as measured by MDA, and is not a genetic risk marker for CAD Caucasians.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 0 0 0 0 1 1 1 0 0 1
13_1,13,The ecNOS gene a/b polymorphism and the NADH/NADPH oxidase p22 phox gene C242T polymorphism were found to be significantly associated with the development of CAD in Korean male patients less than 51 years old.,The p22 phox C242T polymorphism is not associated with the occurrence or severity of CAD or with a history of MI in Australian Caucasian patients aged </= 65 years.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 1 1,0 1 1 0 0 0 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0,0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1,0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 1 0 0 0 0
13_2,13,"Our observations indicate a significant relationship between p22phox C242T and PARP-1 Val762Ala polymorphisms, CAD and its severity, but not with occurrence of MI in T2DM individuals with significant coronary stenoses.",The p22 phox C242T polymorphism is not associated with the occurrence or severity of CAD or with a history of MI in Australian Caucasian patients aged </= 65 years.,0 0 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1,0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 1 1 1 1 1 1 1 1
13_3,13,The ecNOS gene a/b polymorphism and the NADH/NADPH oxidase p22 phox gene C242T polymorphism were found to be significantly associated with the development of CAD in Korean male patients less than 51 years old.,In the total population and in high and low risk groups the relative frequencies of the C242T alleles were essentially the same in patients without or with CAD and in individuals without or with myocardial infarction.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 0 0 1 1 1 1 1 0 1 1 0 0 0 1 0 0 0 0 0 0 1 1 1 0 0 0 0 1 1 1 1 1
13_4,13,The ecNOS gene a/b polymorphism and the NADH/NADPH oxidase p22 phox gene C242T polymorphism were found to be significantly associated with the development of CAD in Korean male patients less than 51 years old.,The p22 phox codon 72 polymorphism is not associated with the risk of CHD in the present samples of Asian Indians and Chinese.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1
13_5,13,The T allele in the C242T polymorphism of the p22phox gene had a protective effect against the development of CAD despite the exposure of study subjects to risk factors related to excessive NADPH-dependent superoxide production.,"It is concluded that the C242T polymorphism of the p22 phox gene is not associated with lipid peroxidation as measured by MDA, and is not a genetic risk marker for CAD Caucasians.",0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 1 1 1 0 0 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 0 0 0 0 1 1 1 0 0 1
13_6,13,"In addition, the rs13306294 A allele is a potential factor of stenosis of coronary arteries that increases susceptibility for the extent of disease.",Our null results provide no support for the hypothesis that any of the 85 genetic variants tested is a susceptibility factor for ACS.,0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 1 1 1 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0,0 0 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 1 1 0 1 0 0,0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0 0 0 0 0 1
13_7,13,"Accumulation of gene polymorphisms related to oxidative stress is likely associated with the prevalence of MI in type 2 diabetic patients, suggesting that the combined information about these variants is useful to assess the risk of MI.","It is concluded that the C242T polymorphism of the p22 phox gene is not associated with lipid peroxidation as measured by MDA, and is not a genetic risk marker for CAD Caucasians.",0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 0 1 1 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 1 1 0 1 1 1 0 0 0 0 1 1 1 1 1 1
13_8,13,The ecNOS gene a/b polymorphism and the NADH/NADPH oxidase p22 phox gene C242T polymorphism were found to be significantly associated with the development of CAD in Korean male patients less than 51 years old.,The A640G and the C242T polymorphisms were not associated with severity of CAD and endothelial function.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 0 1 1 0 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1,0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0,0 1 0 0 1 1 0 0 0 0 0 0 0 0 1 1
13_9,13,The T allele in the C242T polymorphism of the p22phox gene had a protective effect against the development of CAD despite the exposure of study subjects to risk factors related to excessive NADPH-dependent superoxide production.,The p22 phox C242T polymorphism is not associated with the occurrence or severity of CAD or with a history of MI in Australian Caucasian patients aged </= 65 years.,0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 1 1 1 1 1 1 1 0 0 1 1 1 1,0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1
13_10,13,"Our observations indicate a significant relationship between p22phox C242T and PARP-1 Val762Ala polymorphisms, CAD and its severity, but not with occurrence of MI in T2DM individuals with significant coronary stenoses.","It is concluded that the C242T polymorphism of the p22 phox gene is not associated with lipid peroxidation as measured by MDA, and is not a genetic risk marker for CAD Caucasians.",0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 1 1 1 0 1 0 0 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 0 0 0 0 1 1 1 0 0 1
13_11,13,"Our observations indicate a significant relationship between p22phox C242T and PARP-1 Val762Ala polymorphisms, CAD and its severity, but not with occurrence of MI in T2DM individuals with significant coronary stenoses.",In the total population and in high and low risk groups the relative frequencies of the C242T alleles were essentially the same in patients without or with CAD and in individuals without or with myocardial infarction.,0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 1 1 1 1 1 1 0 1 1 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1
13_12,13,"In conclusion, the CYBA +242C/T and PPARD +294T/C variants modulate risk of CAD through their associations with atherogenic serum lipid profiles.","It is concluded that the C242T polymorphism of the p22 phox gene is not associated with lipid peroxidation as measured by MDA, and is not a genetic risk marker for CAD Caucasians.",0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0,0 0 0 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0 0 0,0 0 0 0 0 1 0 1 1 1 1 1 0 0 0 0 1 1 0 1 1 1 0 0 0 0 0 0 0 0 0 1
13_13,13,"In conclusion, the CYBA +242C/T and PPARD +294T/C variants modulate risk of CAD through their associations with atherogenic serum lipid profiles.",In the total population and in high and low risk groups the relative frequencies of the C242T alleles were essentially the same in patients without or with CAD and in individuals without or with myocardial infarction.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 1 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 1 1 1 1 1 1 0 1 1 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1
13_14,13,"Accumulation of gene polymorphisms related to oxidative stress is likely associated with the prevalence of MI in type 2 diabetic patients, suggesting that the combined information about these variants is useful to assess the risk of MI.",The p22 phox C242T polymorphism is not associated with the occurrence or severity of CAD or with a history of MI in Australian Caucasian patients aged </= 65 years.,0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 0 1 1 1 1 0 0 0 0 0 1 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 1 0 0 1 1 1 1 1 1 1 1
13_15,13,"Accumulation of gene polymorphisms related to oxidative stress is likely associated with the prevalence of MI in type 2 diabetic patients, suggesting that the combined information about these variants is useful to assess the risk of MI.",The p22 phox codon 72 polymorphism is not associated with the risk of CHD in the present samples of Asian Indians and Chinese.,0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 0 1 1 1 1 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1
13_16,13,these results support the increased risk of developing early CAD and of having rapid progression of coronary stenosis in subjects carrying the C242T nucleotide transition among the Italian population.,In the total population and in high and low risk groups the relative frequencies of the C242T alleles were essentially the same in patients without or with CAD and in individuals without or with myocardial infarction.,0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 1 1 1 1 0 1 1 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1
13_17,13,The 242T allele interacts with cigarette smoking and hypercholesterolemia to increase the risk of CAD; this risk is probably associated with the cumulative/synergistic effect of the 242T allele and both the traditional risk factors.,"It is concluded that the C242T polymorphism of the p22 phox gene is not associated with lipid peroxidation as measured by MDA, and is not a genetic risk marker for CAD Caucasians.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 1 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 1 0 1,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 1 1 0 0 1 1 1 0 0 0 0 1 1 0 1 1 1 0 0 0 0 1 0 1 0 0 1
13_18,13,The 242T allele interacts with cigarette smoking and hypercholesterolemia to increase the risk of CAD; this risk is probably associated with the cumulative/synergistic effect of the 242T allele and both the traditional risk factors.,The p22 phox codon 72 polymorphism is not associated with the risk of CHD in the present samples of Asian Indians and Chinese.,0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 1 0 1,0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1
13_19,13,The present study suggests a protective association between the c.-930A>G promoter polymorphism in the p22-PHOX (CYBA) gene and the development of myocardial infarction in young individuals ( 40 years).,"It is concluded that the C242T polymorphism of the p22 phox gene is not associated with lipid peroxidation as measured by MDA, and is not a genetic risk marker for CAD Caucasians.",0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 1 1 1 1 1 1
14_0,14,We think that the results of staged or combined CABG plus CEA surgery are satisfactory in patients with severe carotid disease and advanced coronary artery disease.,"These data demonstrate that the performance of simultaneous CABG and CEA procedures is associated with increased neurologic morbidity (14.3%), both ipsilateral and contralateral to the side of carotid surgery in contrast to staged CABG and CEA (3.4%).",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
14_1,14,We think that the results of staged or combined CABG plus CEA surgery are satisfactory in patients with severe carotid disease and advanced coronary artery disease.,"Despite highly selected populations, contemporary surgical results do not indicate that staged treatment of severe, concomitant coronary and carotid artery occlusive disease has an advantage over simultaneous treatment.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 0 1 1
14_3,14,Patients with combined cardiac and carotid disease benefit from assessment of both systems in order to stage CABG and carotid endarterectomy.,"These data demonstrate that the performance of simultaneous CABG and CEA procedures is associated with increased neurologic morbidity (14.3%), both ipsilateral and contralateral to the side of carotid surgery in contrast to staged CABG and CEA (3.4%).",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 1
14_5,14,Combined procedures can be performed with acceptable risk and with encouraging long-term results also in this special group of patients; they may improve the long-term prognosis of patients with diffuse atherosclerosis much more.,"These data demonstrate that the performance of simultaneous CABG and CEA procedures is associated with increased neurologic morbidity (14.3%), both ipsilateral and contralateral to the side of carotid surgery in contrast to staged CABG and CEA (3.4%).",0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 1 0 0 0 0 1 1 0 0 0 1 1 0 0,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 1 1 0 0 0 0 1 0 1 1
14_6,14,We think that the results of staged or combined CABG plus CEA surgery are satisfactory in patients with severe carotid disease and advanced coronary artery disease.,We identified no significant difference in mortality or neurologic complications between STAGED and SYNC approaches.,0 0 0 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 1 1 0 1 1 0 0 0 0 0 1 1 1 0 0 1 1 1,0 0 1 1 1 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 0 1 1 0 1 1 1 1
14_7,14,Patients with combined cardiac and carotid disease benefit from assessment of both systems in order to stage CABG and carotid endarterectomy.,"Despite highly selected populations, contemporary surgical results do not indicate that staged treatment of severe, concomitant coronary and carotid artery occlusive disease has an advantage over simultaneous treatment.",0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1,0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0,0 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1 0 0 0 0 1 1
14_8,14,Combined procedures can be performed with acceptable risk and with encouraging long-term results also in this special group of patients; they may improve the long-term prognosis of patients with diffuse atherosclerosis much more.,"Despite highly selected populations, contemporary surgical results do not indicate that staged treatment of severe, concomitant coronary and carotid artery occlusive disease has an advantage over simultaneous treatment.",0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 1 1 0 0 0 1 1 0 0,0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0,0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 1 0 0 0 0 0 0
14_9,14,Patients with combined cardiac and carotid disease benefit from assessment of both systems in order to stage CABG and carotid endarterectomy.,"Although the patient population undergoing simultaneous carotid and coronary revascularization may have more severe disease, we believe that combining the procedures during the same operative setting results in an increased perioperative stroke and death rate.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 1 0 0 1 1 1 1 0 0 0 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 1 1 0 1 1
14_10,14,Study patients spent statistically significantly less time in the hospital than control patients (10 vs. 17.9 days).,"Although the patient population undergoing simultaneous carotid and coronary revascularization may have more severe disease, we believe that combining the procedures during the same operative setting results in an increased perioperative stroke and death rate.",0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0,0 0 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 1 1
14_12,14,Combined procedures can be performed with acceptable risk and with encouraging long-term results also in this special group of patients; they may improve the long-term prognosis of patients with diffuse atherosclerosis much more.,We identified no significant difference in mortality or neurologic complications between STAGED and SYNC approaches.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0,1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0,0 1 1 1 1 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 0 1 1 1 1 1 1 1
14_13,14,Patients with combined cardiac and carotid disease benefit from assessment of both systems in order to stage CABG and carotid endarterectomy.,We identified no significant difference in mortality or neurologic complications between STAGED and SYNC approaches.,0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 1 1 0 0 1 1 1 1 0 0 0 1 1 1 1 1,1 1 1 1 1 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 0 1 1 0 1 1 1 1
14_14,14,Study patients spent statistically significantly less time in the hospital than control patients (10 vs. 17.9 days).,We identified no significant difference in mortality or neurologic complications between STAGED and SYNC approaches.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 0 1 1 0 1 0 1 1
14_15,14,Study patients spent statistically significantly less time in the hospital than control patients (10 vs. 17.9 days).,"Despite highly selected populations, contemporary surgical results do not indicate that staged treatment of severe, concomitant coronary and carotid artery occlusive disease has an advantage over simultaneous treatment.",0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0,0 0 0 1 0 0 0 0 0 0 1 1 1 0 0 0 0,0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0,0 1 1 1 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 1 1
15_0,15,Administration of amlodipine to patients with CAD and normal blood pressure resulted in reduced adverse cardiovascular events.,"Low dose (1.25 mg) ramipril once daily has no effect on cardiovascular and renal outcomes of patients with type 2 diabetes and albuminuria, despite a slight decrease in blood pressure and urinary albumin.",0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0,0 0 1 1 1 1 1 1 1 0 0 0 0 1 1 1 1,0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 0 0 0 0 1 1 1 1 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 1 1
15_1,15,"Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.","Low dose (1.25 mg) ramipril once daily has no effect on cardiovascular and renal outcomes of patients with type 2 diabetes and albuminuria, despite a slight decrease in blood pressure and urinary albumin.",0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 1 1 1 1 1 0 1 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 1 1 0 0 0 0 1 1 1 1 0 1 1 1 1 1 1 1 0 0 0 0 0 1 1 0 1 1
15_2,15,"Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.","In patients at low risk of cardiovascular events after CABG, routine early initiation of angiotensin-converting enzyme inhibitor therapy does not appear to improve clinical outcome up to 3 years after CABG; however, it increases the incidence of adverse events, particularly early after CABG.",0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 1 1 1 1 1 0 1 0 0 0 0 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0,0 0 0 1 1 1 1 1 1 1 1 1 0 0 1 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 1 1 1 1 0 1 1 1
15_3,15,Administration of amlodipine to patients with CAD and normal blood pressure resulted in reduced adverse cardiovascular events.,"In patients at low risk of cardiovascular events after CABG, routine early initiation of angiotensin-converting enzyme inhibitor therapy does not appear to improve clinical outcome up to 3 years after CABG; however, it increases the incidence of adverse events, particularly early after CABG.",0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0,0 0 1 0 1 1 1 1 1 1 1 0 0 0 0 1 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0,0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 1 1 1 1
15_4,15,"Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.",Quinapril 20 mg did not significantly affect the overall frequency of clinical outcomes or the progression of coronary atherosclerosis.,0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 1 1 1 1 1 0 1 0 0 0 0 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1,0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 0 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1
15_5,15,Benazepril provides protection against the progression of renal insufficiency in patients with various renal diseases.,"Low dose (1.25 mg) ramipril once daily has no effect on cardiovascular and renal outcomes of patients with type 2 diabetes and albuminuria, despite a slight decrease in blood pressure and urinary albumin.",0 1 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 1 0 0 1 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 0 0 0 0 1 1 1 1 0 1 1 1 1 1 1 1 0 0 0 0 0 1 1 0 1 1
15_6,15,Combination therapy with perindopril and indapamide produced larger blood pressure reductions and larger risk reductions than did single drug therapy with perindopril alone.,"Low dose (1.25 mg) ramipril once daily has no effect on cardiovascular and renal outcomes of patients with type 2 diabetes and albuminuria, despite a slight decrease in blood pressure and urinary albumin.",0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 0 1 0 0 1 0 1 1 1 1 0 1 1 1 1 1 1,0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 0 0 0 0 1 1 1 1 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 1 1
15_7,15,Benazepril provides protection against the progression of renal insufficiency in patients with various renal diseases.,"In patients at low risk of cardiovascular events after CABG, routine early initiation of angiotensin-converting enzyme inhibitor therapy does not appear to improve clinical outcome up to 3 years after CABG; however, it increases the incidence of adverse events, particularly early after CABG.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 1 0 0 1 1 1 1 0 0 0 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 1 1 1 1 0 1 1 1
15_8,15,Benazepril provides protection against the progression of renal insufficiency in patients with various renal diseases.,Quinapril 20 mg did not significantly affect the overall frequency of clinical outcomes or the progression of coronary atherosclerosis.,0 1 1 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 0 0 1 1 0 0 1 1 1 1,0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 0 0 0 0 0 1 1 1 1 1 0 0 0 0 1 1
15_9,15,Administration of amlodipine to patients with CAD and normal blood pressure resulted in reduced adverse cardiovascular events.,The results provide no support for the hypothesis that reduced atherosclerosis is responsible for the beneficial effects of ACE inhibitors on major coronary events.,0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0,0 0 1 0 1 1 1 1 1 1 1 0 0 0 1 0 0,0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 1 0 1 0 0
15_10,15,Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.,"Low dose (1.25 mg) ramipril once daily has no effect on cardiovascular and renal outcomes of patients with type 2 diabetes and albuminuria, despite a slight decrease in blood pressure and urinary albumin.",0 1 1 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0,1 0 0 1 1 0 1 1 1 1 1 0 0 0 0 0 1 1 1 1,0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 0 0 0 0 1 1 0 1 0 1 1 1 1 1 1 1 0 0 0 0 0 1 1 0 1 1
15_11,15,Combination therapy with perindopril and indapamide produced larger blood pressure reductions and larger risk reductions than did single drug therapy with perindopril alone.,"In patients at low risk of cardiovascular events after CABG, routine early initiation of angiotensin-converting enzyme inhibitor therapy does not appear to improve clinical outcome up to 3 years after CABG; however, it increases the incidence of adverse events, particularly early after CABG.",0 0 0 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0,1 1 0 1 0 1 0 0 1 1 0 0 0 1 0 1 0 1 1 1 0 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 1 1 1 1 1 1 0 0 1 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 1 1 1 1 0 1 1 1
15_12,15,"Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.",The results provide no support for the hypothesis that reduced atherosclerosis is responsible for the beneficial effects of ACE inhibitors on major coronary events.,0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 1 1 1 1 1 0 1 0 0 0 0 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1,0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 1 0 1 1 1
15_13,15,Benazepril provides protection against the progression of renal insufficiency in patients with various renal diseases.,The results provide no support for the hypothesis that reduced atherosclerosis is responsible for the beneficial effects of ACE inhibitors on major coronary events.,0 1 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 1 1 0 1 1 1 1 1 1 1 1 1 1,0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 0 1 1 0 0 0 0 1 1 1 1 1 0 1 1 1
15_14,15,"Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome.","Low dose (1.25 mg) ramipril once daily has no effect on cardiovascular and renal outcomes of patients with type 2 diabetes and albuminuria, despite a slight decrease in blood pressure and urinary albumin.",0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0,1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0,0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 0 0 0 0 1 1 1 0 0 1 1 1 1 1 1 1 0 0 0 0 0 1 1 0 1 1
15_15,15,"Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome.",Quinapril 20 mg did not significantly affect the overall frequency of clinical outcomes or the progression of coronary atherosclerosis.,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0,1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0,0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 0 0 0 0 0 1 1 0 1 0 0 0 1 1 1 1
15_16,15,"Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome.","In patients at low risk of cardiovascular events after CABG, routine early initiation of angiotensin-converting enzyme inhibitor therapy does not appear to improve clinical outcome up to 3 years after CABG; however, it increases the incidence of adverse events, particularly early after CABG.",0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0,0 0 0 1 1 1 1 1 1 1 1 1 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 1 1 1 1 1 1 1 1 1 0 0 1 1 1 0 0 0 0 0 0 1 0 1 1 1 1 1 1 0 0 0 0 1 1 1 1 0 1 1 1
15_17,15,Combination therapy with perindopril and indapamide produced larger blood pressure reductions and larger risk reductions than did single drug therapy with perindopril alone.,Quinapril 20 mg did not significantly affect the overall frequency of clinical outcomes or the progression of coronary atherosclerosis.,0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 0 1 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1,0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 0 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1
15_18,15,"Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome.",The results provide no support for the hypothesis that reduced atherosclerosis is responsible for the beneficial effects of ACE inhibitors on major coronary events.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 1 1 1 1 0 1 1 1
15_19,15,Administration of amlodipine to patients with CAD and normal blood pressure resulted in reduced adverse cardiovascular events.,Quinapril 20 mg did not significantly affect the overall frequency of clinical outcomes or the progression of coronary atherosclerosis.,0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0,0 0 1 0 0 1 1 1 1 1 1 0 0 0 1 1 1,0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 0 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1
16_0,16,"In this population, moderate intake of fatty fish and marine omega-3 fatty acids was associated with lower rates of HF, though the association for fish intake was not statistically significant; higher intake was not associated with additional benefit.",Our findings do not support a major role for fish intake in the prevention of heart failure.,0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 1 0 0 1 0 0 1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0,0 0 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
16_1,16,Moderate consumption of fatty fish (1-2 servings per week) and marine omega-3 fatty acids were associated with a lower rate of first HF hospitalization or death in this population.,Our findings do not support a major role for fish intake in the prevention of heart failure.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 1 0 1 1 1 1 0 1 1 1 1 0 0 0 0 1 1 1 1 1 1 0 1 1 1 1,0 0 1 1 1 1 0 1 0 0 0 1 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1
16_2,16,"Increased baked/broiled fish intake may lower HF risk, whereas increased fried fish intake may increase HF risk in postmenopausal women.",Our findings do not support a major role for fish intake in the prevention of heart failure.,0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 0 0 0 0 0 0 0 0 1 1 1 0 1 1 1 0 1 1,0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
17_0,17,"In this large, population-based sample of African-American and white adults, whole-grain intake was associated with lower HF risk, whereas intake of eggs and high-fat dairy were associated with greater HF risk after adjustment for several confounders.",Our findings do not support a major role for fish intake in the prevention of heart failure.,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0,0 0 1 1 0 0 1 1 1 1 1 0 0 0 0 0 0 1 0 0 0 1 0 1 1 0 0 0 0 0 1 1 1 1 1 1,0 0 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0
17_1,17,Moderate consumption of fatty fish (1-2 servings per week) and marine omega-3 fatty acids were associated with a lower rate of first HF hospitalization or death in this population.,Our findings do not support a major role for fish intake in the prevention of heart failure.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 1 0 1 1 1 1 0 1 1 1 1 0 0 0 0 1 1 0 1 0 1 0 1 1 1 1,0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
17_2,17,"Increased baked/broiled fish intake may lower HF risk, whereas increased fried fish intake may increase HF risk in postmenopausal women.",Our findings do not support a major role for fish intake in the prevention of heart failure.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 1 1 1 1 0 0 0 0 0 1 1 1 1 0 0 0,0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0,0 0 1 1 1 1 1 1 0 0 0 1 0 0 0 1 1
17_3,17,"Among older adults, consumption of tuna or other broiled or baked fish, but not fried fish, is associated with lower incidence of CHF.",Our findings do not support a major role for fish intake in the prevention of heart failure.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0,0 1 1 0 0 1 0 0 1 0 1 0 1 1 1 0 0 0 0 1 1 1 1,0 0 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
18_0,18,"Relatively low-dose candesartan, which did not alter blood pressure levels, reduces cardiovascular risk in high-risk patients with CAD.","Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 0 0 0 0 1 1 0 0 0 1 0 1 0 0 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 1 1 1 1 1 1 0 0 0 1 0 1 1 0 0 1 1 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 1 0 0 1
18_1,18,"Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.","The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 1 1
18_2,18,Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria.,"The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 1 1 1 1 1 1 1
18_3,18,"Although the drug had no significant effect on the primary outcome of this study, which included hospitalisations for heart failure, it modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction, or stroke.","Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 1 1 1 1 1 1 0 1 1 1 0 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 1 1 1 1 1 1 1 1 1 0 0 0 1 0 1 1 0 0 1 1 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1
18_4,18,Treatment with candesartan in type 2 diabetic patients with mild to moderate retinopathy might induce improvement of retinopathy.,"The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy.",0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0,0 0 1 0 0 0 0 0 1 1 1 1 1 0 0 0 0 1,0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 0 1 1 1 1 1 1 1
18_5,18,"Relatively low-dose candesartan, which did not alter blood pressure levels, reduces cardiovascular risk in high-risk patients with CAD.","The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 0 0 0 0 1 1 1 0 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 0 0 0 1 1 1 1 1 1 1 1 1 0 0 1 1 0 1 1 1 1 1 1 1
18_6,18,"In elderly hypertensive patients, a slightly more effective blood pressure reduction during candesartan-based therapy, compared with control therapy, was associated with a modest, statistically non-significant, reduction in major cardiovascular events and with a marked reduction in non-fatal stroke.","Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 0 0 0 1 1 1 0 1 0 1 1 1 0 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 1 1 1 1 1 1 1 1 1 0 0 0 1 0 1 1 0 0 1 1 0 0 0 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0
18_7,18,Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria.,"Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 1 1 1 1 1 1 0 0 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 1 1 1 1 1 1 1 1 1 0 0 0 1 0 1 1 0 0 1 1 0 0 0 1 1 1 1 0 0 1 1 1 0 0 0 0 0 1 1 1 1
18_8,18,"Although the drug had no significant effect on the primary outcome of this study, which included hospitalisations for heart failure, it modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction, or stroke.","Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 1 1 1 1 1 0 0 1 1 1 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 1 1 1 0 1 1 1 1 0 0 0 0 0 1 1 1 0 1 0 1 0 1
18_10,18,"Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards.","Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.",0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 1 1,0 0 0 1 1 0 0 1 1 0 0 0 0 0 0 1 0 1 1 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0
18_11,18,Treatment with candesartan in type 2 diabetic patients with mild to moderate retinopathy might induce improvement of retinopathy.,"Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 0 1 1 1 0 1 1 1 1 1 0 0 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 1 1 1 1 1 1 0 0 0 1 0 1 1 0 0 1 1 0 0 0 1 0 0 1 0 0 1 1 1 0 0 0 0 0 1 1 1 1
18_12,18,"Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.","Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.",0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 1 0 1 1 1 1 1 1 1 1 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 1 1 1 1 0 1 1 1 0 0 0 1 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 1 1
18_14,18,"Relatively low-dose candesartan, which did not alter blood pressure levels, reduces cardiovascular risk in high-risk patients with CAD.","Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes.",0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0,0 1 1 0 0 0 0 1 1 1 0 0 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 1 1 1 1 1 0 1 0 1
18_15,18,"In elderly hypertensive patients, a slightly more effective blood pressure reduction during candesartan-based therapy, compared with control therapy, was associated with a modest, statistically non-significant, reduction in major cardiovascular events and with a marked reduction in non-fatal stroke.","Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 0 0 0 1 1 1 0 1 0 1 1 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0,0 0 1 0 1 1 1 1 1 0 1 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 1
18_16,18,"In elderly hypertensive patients, a slightly more effective blood pressure reduction during candesartan-based therapy, compared with control therapy, was associated with a modest, statistically non-significant, reduction in major cardiovascular events and with a marked reduction in non-fatal stroke.","The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 1,0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 0 0 1 0 0 0 0 0 0 1 1 1 1 1 1 0 0 1 1 0 1 1 1 1 1 1 1
18_17,18,"Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards.","The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 0 0 0 0 0 1 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1
18_18,18,Treatment with candesartan in type 2 diabetic patients with mild to moderate retinopathy might induce improvement of retinopathy.,"Although candesartan reduces the incidence of retinopathy, we did not see a beneficial effect on retinopathy progression.",0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1,0 0 0 0 1 1 1 0 0 1 1 1 1 0 0 0 0 0,0 0 0 0 0 0 0 1 1 1 1 0 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
18_19,18,"Relatively low-dose candesartan, which did not alter blood pressure levels, reduces cardiovascular risk in high-risk patients with CAD.","Although candesartan reduces the incidence of retinopathy, we did not see a beneficial effect on retinopathy progression.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 0 0 0 0 0 1 1 1 0 1 1 0 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 1 1
19_0,19,Physical training in warm water was well tolerated and seems to improve exercise capacity as well as muscle function in small muscle groups in patients with CHF.,This exercise intervention did not improve exercise capacity or quality of life in older patients with heart failure and was not cost saving to the National Health Service.,0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 0 0 0 0,0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0 0 0 0 0 1 1 1 0 0 1 1 1
19_1,19,Elderly patients with chronic heart failure can benefit from an appropriately designed exercise programme and should not be excluded from future large scale trials.,This exercise intervention did not improve exercise capacity or quality of life in older patients with heart failure and was not cost saving to the National Health Service.,0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 1 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0,0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 0 0 0 1 1 0 1 1 1 0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1
19_2,19,"Cardiac rehabilitation, already widely established in the UK, offers an effective model of care for older patients with heart failure.",This exercise intervention did not improve exercise capacity or quality of life in older patients with heart failure and was not cost saving to the National Health Service.,0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0,1 1 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0,0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 0 1 1 0 1 1 1 0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1
19_3,19,"Cardiac rehabilitation, already widely established in the UK, offers an effective model of care for older patients with heart failure.","In older patients with HFrEF, ET failed to produce consistent benefits in any of the four pivotal domains of HF that were examined, although the heterogeneous response of older patients with HFrEF to ET requires further investigation to better determine which patients with HFrEF will respond favorably to ET.",0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0,1 1 0 0 0 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1,0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 0 0 0 1 1 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
19_4,19,Exercise training is equally effective in patients aged younger than and older than 65 years.,This exercise intervention did not improve exercise capacity or quality of life in older patients with heart failure and was not cost saving to the National Health Service.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 0 1 1 0 0 1 1 1 1 0 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 0 0 0 1 1 0 1 1 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 1 1
19_5,19,Physical training in warm water was well tolerated and seems to improve exercise capacity as well as muscle function in small muscle groups in patients with CHF.,"In older patients with HFrEF, ET failed to produce consistent benefits in any of the four pivotal domains of HF that were examined, although the heterogeneous response of older patients with HFrEF to ET requires further investigation to better determine which patients with HFrEF will respond favorably to ET.",0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 0 1 1 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
19_6,19,Exercise training is equally effective in patients aged younger than and older than 65 years.,"In older patients with HFrEF, ET failed to produce consistent benefits in any of the four pivotal domains of HF that were examined, although the heterogeneous response of older patients with HFrEF to ET requires further investigation to better determine which patients with HFrEF will respond favorably to ET.",0 0 1 1 1 0 0 0 0 0 0 0 0 0 0,1 1 0 0 0 0 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 0 1 1 0 1 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
19_7,19,Elderly patients with chronic heart failure can benefit from an appropriately designed exercise programme and should not be excluded from future large scale trials.,"In older patients with HFrEF, ET failed to produce consistent benefits in any of the four pivotal domains of HF that were examined, although the heterogeneous response of older patients with HFrEF to ET requires further investigation to better determine which patients with HFrEF will respond favorably to ET.",0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
20_0,20,"Home telemonitoring in a typical elderly population of heart failure patients produces a similar outcome to 'usual' specialist care, but reduces clinic and emergency room visits and unplanned heart failure rehospitalizations at little additional cost.",Daily electronic transmission of body weight and monitoring three times a week did not decrease hospitalization or death in HF patients followed up at a HF clinic.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 1 0 0 0 0 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1
20_1,20,Home-based exercise training programmes may not be appropriate for community-based heart failure patients.,Telemedicine management may not be appropriate for all HF patients.,0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 0 0 1 0 0 0,0 0 0 0 0 0 0 0 0 0,1 1 0 0 0 0 0 1 0 0
20_2,20,"Despite no difference in the primary end point of rehospitalization rates, mortality was significantly reduced for patients randomized to the AlereNet system without an increase in utilization, despite specialized and aggressive heart failure care in both groups.","Despite effective implementation of an Internet-based telehealth intervention in an elderly HF population, there was no discernible impact on overall morbidity or mortality.",0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 1 1 1 0 1 1 0 0 0 0 0 0 1 1 1 1 1 1 0 1 1 1 0 1 1 1 0 0 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0,0 0 0 0 0 1 1 1 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0
20_3,20,Subgroup analysis of patients who lived locally and saw a cardiologist showed a significant decrease in CHF readmissions for the intervention group (P =.03).,Daily electronic transmission of body weight and monitoring three times a week did not decrease hospitalization or death in HF patients followed up at a HF clinic.,0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0,0 0 0 0 1 1 1 0 1 1 1 0 0 0 0 0 0 1 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 1 0 1 0 0 0 1 1 1 1 1 1
20_5,20,"Home or Hospital in Heart failure indicates that self-managed HT of clinical and physiological parameters is feasible in HF patients, with surprisingly high compliance.",Daily electronic transmission of body weight and monitoring three times a week did not decrease hospitalization or death in HF patients followed up at a HF clinic.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 0 1 1 1 1 1 0 0 0 1 0 1 0 0 0 1 1 1 1 1 1
20_6,20,"Telemonitoring-facilitated collaboration between GPs and a heart failure clinic reduces mortality and number of days lost to hospitalization, death, or dialysis in CHF patients.",Daily electronic transmission of body weight and monitoring three times a week did not decrease hospitalization or death in HF patients followed up at a HF clinic.,0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 1 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0
20_8,20,"The results indicate that total treatment costs and mortality rate can be reduced by telemetric monitoring of patients in CHF, especially in men.",Daily electronic transmission of body weight and monitoring three times a week did not decrease hospitalization or death in HF patients followed up at a HF clinic.,0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0,0 0 0 0 1 1 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 0 0 1 1 1 1 0 0 0 1 0 0 0 0 0 1 1 1 1 1 1
20_9,20,Telehealth technologies are a viable means of providing home monitoring to patients with heart disease at high risk of hospital readmission to improve their self-care abilities.,Daily electronic transmission of body weight and monitoring three times a week did not decrease hospitalization or death in HF patients followed up at a HF clinic.,0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 0 0 0 1 1,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 1 0 1 1 0 0 0 0 1 1
20_10,20,Telehealth technologies are a viable means of providing home monitoring to patients with heart disease at high risk of hospital readmission to improve their self-care abilities.,"Caregiver mastery, informal social support, and electronic home monitoring were not significant predictors for risk of hospital readmission.",0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 0 0 0 0 0 0 0 0 1 1 1 1 0 1 0 0 0 0 0 0 0 1 1,0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0,1 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0
20_12,20,Further investigation and refinement of the application of HTM are warranted because it may be a valuable role for the management of selected patients with heart failure.,Daily electronic transmission of body weight and monitoring three times a week did not decrease hospitalization or death in HF patients followed up at a HF clinic.,0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 1 0 0 0 0 0 0,1 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0,1 1 1 0 1 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
20_13,20,Further investigation and refinement of the application of HTM are warranted because it may be a valuable role for the management of selected patients with heart failure.,Telemedicine management may not be appropriate for all HF patients.,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0,0 0 1 1 1 1 0 0 0 0,1 1 0 0 0 0 0 1 0 0
20_14,20,"Home or Hospital in Heart failure indicates that self-managed HT of clinical and physiological parameters is feasible in HF patients, with surprisingly high compliance.","Despite effective implementation of an Internet-based telehealth intervention in an elderly HF population, there was no discernible impact on overall morbidity or mortality.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1,1 0 1 0 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0,0 0 0 0 0 1 1 1 0 0 1 0 0 0 0 0 0 0 0 1 1 1 1
20_15,20,"Home or Hospital in Heart failure indicates that self-managed HT of clinical and physiological parameters is feasible in HF patients, with surprisingly high compliance.","Caregiver mastery, informal social support, and electronic home monitoring were not significant predictors for risk of hospital readmission.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 1 0 1 1 1 1 1 0 0 1 1 1 0 0 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 0 0 0 0 0 0 0 1 0 1 1 1 1
20_16,20,"Although disease management is effective in the mainstream HF patient population, in Hispanics this ill, elderly, and poorly educated, a different approach may be needed.","Despite effective implementation of an Internet-based telehealth intervention in an elderly HF population, there was no discernible impact on overall morbidity or mortality.",0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 1 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 0,0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1
20_17,20,"Although disease management is effective in the mainstream HF patient population, in Hispanics this ill, elderly, and poorly educated, a different approach may be needed.",Daily electronic transmission of body weight and monitoring three times a week did not decrease hospitalization or death in HF patients followed up at a HF clinic.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 0 0 1 0 0 0 1 1 0 1 1 0 1 1 0 1 1 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 1 0 1 0 0 0 1 1 1 1 1 1
20_18,20,"Although disease management is effective in the mainstream HF patient population, in Hispanics this ill, elderly, and poorly educated, a different approach may be needed.",Telemedicine management may not be appropriate for all HF patients.,0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 0 0 0 0 1 0 0 0 1 1 0 1 1 0 1 1 0 0 0 0 0 0,0 0 1 1 1 1 0 0 0 0,1 1 0 0 0 0 0 1 0 0
20_19,20,Short-term reductions in the heart failure hospitalization rate were associated with the use of automated home monitoring equipment.,Daily electronic transmission of body weight and monitoring three times a week did not decrease hospitalization or death in HF patients followed up at a HF clinic.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 0 1 1 0 0 0 0 0 0 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1
21_0,21,Atorvastatin therapy seems to be associated with decreased incidence of SCD in patients with advanced chronic heart failure.,"Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe.",0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 0 0 1 1 1 1 0 0 0 1 0 0 0,0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1
21_1,21,"In chronic heart failure, treatment with statins is related to lower mortality, independent of cholesterol levels, disease etiology and clinical status.","Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe.",0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 0 1 1,0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1
21_2,21,"Among adults diagnosed with heart failure who had no prior statin use, incident statin use was independently associated with lower risks of death and hospitalization among patients with or without coronary heart disease.","Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 1 0 0 1 1 1 1 1 1 0 0 1 1 1 1 1 1,0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 1 1 0 0 0 1 0 0 1 1 1 1 1 1 1 1 1
21_3,21,Atorvastatin therapy seems to be associated with decreased incidence of SCD in patients with advanced chronic heart failure.,"Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations.",0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 0 0 0 1 1 1 0 0 0 1 1 0 0,0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 1 0 0 1 0 0 0 0 0 0 0 0 1 1 1 1
21_4,21,"In conclusion, simvastatin therapy improves LV systolic function and decreases mortality, restenosis, and repeat PCI rate in patients with ischemic heart failure who underwent PCI for acute myocardial infarction.","Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe.",0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 0 0 1 1 1 0 0 1 1 0 1 1 1 0 0 0 1 0 0 1 1 1 1 1 1 1,0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 1 1 0 0 0 1 0 0 1 1 1 1 1 1 1 1 1
21_6,21,"In chronic heart failure, treatment with statins is related to lower mortality, independent of cholesterol levels, disease etiology and clinical status.","Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations.",0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0,1 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0,0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
21_7,21,"Among adults diagnosed with heart failure who had no prior statin use, incident statin use was independently associated with lower risks of death and hospitalization among patients with or without coronary heart disease.","Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 1 0 0 0 1 0 0 0 0 0 0 1 1 1 1 1 1,0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 0 0 1 0 0 1 1 1 0 1 0 0 1 0 0 0 0 0 0 0 0 1 1 1 0
21_8,21,The use of statin therapy in this nonrandomized trial was associated with a significant reduction in all-cause mortality and cardiac morbidity.,"Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe.",0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0,0 0 0 1 0 0 0 1 1 0 0 0 0 0 1 1 1 1 1 1 1,0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
21_9,21,The commencement of treatment with statins is associated with a dose-dependent reduction of the mortality and of the morbidity of patients with ndHF (systolic or non-systolic).,"Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 0 1 0 0 0 0 1 1 0 0 0 0 0 0 1 1 1 1 1 0 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 0 0 0 0 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1
21_10,21,"In patients with heart failure, statin treatment appears to be independently associated with better survival.","Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations.",0 0 0 0 0 0 0 1 1 1 1 1 1 1 1,0 0 0 0 0 1 1 0 0 0 0 0 0 0 0,0 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 0 0 0 0 0 0 0 0 1 1
21_11,21,Statin therapy is associated with a reduction in overall mortality in patients with ischemic or nonischemic cardiomyopathy with an ICD implanted for either primary or secondary prevention.,"Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations.",0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1,0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 0 0 1 0 0 1 1 1 0 1 0 0 1 1 1 0 0 0 0 0 0 1 1 1 1
21_12,21,Initiation and maintenance of treatment with statins is associated with better survival in patients with LVSD.,"Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe.",0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0,1 1 1 0 0 0 1 0 0 0 1 1 1 1 1 1,0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
21_13,21,Initiation and maintenance of treatment with statins is associated with better survival in patients with LVSD.,"Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 0 1 0 0 0 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 0 1 1 1 0 0 0 0 0 0 1 1 1 1
21_14,21,The use of statin therapy in this nonrandomized trial was associated with a significant reduction in all-cause mortality and cardiac morbidity.,"Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations.",0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0,0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1,0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 1
21_15,21,The commencement of treatment with statins is associated with a dose-dependent reduction of the mortality and of the morbidity of patients with ndHF (systolic or non-systolic).,"Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 1 0 0 0 0 0 1 1 1 1 1 1 1 0 0 1 1 1 1 1
21_16,21,"In patients with heart failure, statin treatment appears to be independently associated with better survival.","Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe.",0 0 0 0 0 0 0 1 1 1 0 1 1 0 0,0 0 0 0 0 1 0 0 0 0 1 0 0 1 1,0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 1 1 0 0 0 1 0 0 1 1 1 1 1 1 1 1 1
21_17,21,"Atorvastatin shortens QTc, QTcd and improves cardiac function, and might thereby be parts of the mechanisms which atorvastatin benefited CHF patients secondary to CAD.","Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe.",0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1,0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1
21_18,21,"Atorvastatin shortens QTc, QTcd and improves cardiac function, and might thereby be parts of the mechanisms which atorvastatin benefited CHF patients secondary to CAD.","Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 1 0 0 1 0 0 0 0 0 0 0 0 1 1 1 1
21_19,21,Statin therapy may be associated with improved survival in patients with HF and a normal EF.,"Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe.",0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0,1 0 0 0 0 0 1 1 0 0 0 0 0 0 1 1,0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 1 1 0 0 0 1 0 0 1 1 1 1 1 1 1 1 1
22_0,22,Transplantation of BMC is associated with moderate but significant improvement in the left ventricular ejection fraction after 3 months.,"Injection of autologous BMCs directly into the scar or into the artery supplying the scar is safe but does not improve contractility of nonviable scarred myocardium, reduce scar size, or improve left ventricular function more than CABG alone.",0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 0 0 0 0 1 1 1 1 1 1 1 1 0 1 0 0 1 0 1 1 1
22_1,22,"Intramyocardial bone marrow cell transplantation to patients with ischemic heart failure is safe and improved survival, clinical symptoms, and has beneficial effect on LV function.","Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 0,1 1 1 1 1 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0,0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 0 0 0 1 1 1 1 0 1 1 1
22_2,22,"Thus, the present study demonstrates the relative safety of intramyocardial injections of bone marrow-derived stem cells in humans with severe heart failure and the potential for improving myocardial blood flow with associated enhancement of regional and global left ventricular function.","Injection of autologous BMCs directly into the scar or into the artery supplying the scar is safe but does not improve contractility of nonviable scarred myocardium, reduce scar size, or improve left ventricular function more than CABG alone.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 1 1 0 1 1 1 0 0 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1
22_3,22,"Intramyocardial delivery of purified bone marrow stem cells together with CABG surgery is safe and provides beneficial effects, though it remains to be seen whether thewe effects produce a lasting clinical advantage.","Injection of autologous BMCs directly into the scar or into the artery supplying the scar is safe but does not improve contractility of nonviable scarred myocardium, reduce scar size, or improve left ventricular function more than CABG alone.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 0 1 0 1
22_4,22,"In summary, patients with a previous MI and chronic heart failure could potentially benefit from isolated CABG (i.e., those who received CABG only) combined with BMMNCs delivered through a graft vessel.","Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.",0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0,0 0 0 0 1 0 0 1 1 1 1 1 1 1 1 0 0 0 1 1 1 1 1 1 1 1
22_5,22,"Thus, the present study demonstrates the relative safety of intramyocardial injections of bone marrow-derived stem cells in humans with severe heart failure and the potential for improving myocardial blood flow with associated enhancement of regional and global left ventricular function.","Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.",0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 0 1 0 0 1 1 1 1 0 0 0 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0,0 0 0 1 1 0 0 1 0 0 1 1 1 1 1 0 0 0 1 1 1 1 0 1 1 1
22_6,22,MN-BMC transplantation improves cardiac function and regional perfusion in ischemic heart failure patients during CABG.,"Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.",0 0 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 1 1 0 1 1 0 0 0 0 0 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0,0 0 0 1 0 0 0 1 1 1 1 0 1 1 1 0 0 0 1 1 1 1 0 1 1 1
22_7,22,Autologous stem cell transplantation led to significant improvement in cardiac function in patients undergoing off-pump coronary artery bypass grafting for ischemic cardiomyopathy.,"Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.",0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0,0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 0 0 0 1 1 1 1 0 1 1 1
22_8,22,Autologous stem cell transplantation led to significant improvement in cardiac function in patients undergoing off-pump coronary artery bypass grafting for ischemic cardiomyopathy.,"Injection of autologous BMCs directly into the scar or into the artery supplying the scar is safe but does not improve contractility of nonviable scarred myocardium, reduce scar size, or improve left ventricular function more than CABG alone.",0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 1 1 1 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0,1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0 0 0 0 1 1 1 1 1 0 1 1 1 0 1 1 0 0 0 0 1
22_9,22,"Intramyocardial delivery of purified bone marrow stem cells together with CABG surgery is safe and provides beneficial effects, though it remains to be seen whether thewe effects produce a lasting clinical advantage.","Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.",0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 1 1 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0,0 0 0 1 1 1 1 1 1 0 1 1 0 0 1 0 0 0 1 0 1 1 0 1 1 1
22_10,22,"Intramyocardial bone marrow cell transplantation to patients with ischemic heart failure is safe and improved survival, clinical symptoms, and has beneficial effect on LV function.","Injection of autologous BMCs directly into the scar or into the artery supplying the scar is safe but does not improve contractility of nonviable scarred myocardium, reduce scar size, or improve left ventricular function more than CABG alone.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0,1 0 0 0 1 0 0 1 1 1 1 0 0 0 0 1 1 1 0 0 0 0 0 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 0 1 1 1
22_11,22,Transplantation of BMC is associated with moderate but significant improvement in the left ventricular ejection fraction after 3 months.,"Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.",0 0 0 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0,1 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0,0 0 0 1 1 1 1 1 1 0 1 0 1 1 1 0 0 0 1 1 1 1 0 1 1 1
22_12,22,"In summary, patients with a previous MI and chronic heart failure could potentially benefit from isolated CABG (i.e., those who received CABG only) combined with BMMNCs delivered through a graft vessel.","Injection of autologous BMCs directly into the scar or into the artery supplying the scar is safe but does not improve contractility of nonviable scarred myocardium, reduce scar size, or improve left ventricular function more than CABG alone.",0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 1 1 1 1 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0 0 0 0 1 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1
22_13,22,MN-BMC transplantation improves cardiac function and regional perfusion in ischemic heart failure patients during CABG.,"Injection of autologous BMCs directly into the scar or into the artery supplying the scar is safe but does not improve contractility of nonviable scarred myocardium, reduce scar size, or improve left ventricular function more than CABG alone.",0 0 1 0 0 0 0 0 0 0 0 0 0 0 0,1 1 0 1 1 0 1 1 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 1 1 1 0 0 0 1
23_0,23,"In patients with HCM, myocardial fibrosis as measured by late gadolinium enhancement cardiovascular magnetic resonance is an independent predictor of adverse outcome.",These data suggest an important role for myocardial fibrosis in the clinical course of HCM patients but are not sufficient at this time to consider DE as an independent risk factor for adverse prognosis.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0,0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0,0 0 0 0 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
23_1,23,"If replicated, LGE may be considered an important risk factor for sudden death in patients with HCM.",These data suggest an important role for myocardial fibrosis in the clinical course of HCM patients but are not sufficient at this time to consider DE as an independent risk factor for adverse prognosis.,0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0,0 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0,0 1 0 0 0 0 0 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
23_2,23,"Among our population of largely low or asymptomatic HCM patients, the presence of scar indicated by CMR is a good independent predictor of all-cause and cardiac mortality.",These data suggest an important role for myocardial fibrosis in the clinical course of HCM patients but are not sufficient at this time to consider DE as an independent risk factor for adverse prognosis.,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0,0 0 1 1 1 1 1 1 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 1 0 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0,0 0 0 0 0 0 0 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
24_0,24,"This study provides some support for the concept of the risk of developing end-stage heart failure due to dilated cardiomyopathy being associated with possession of HLA DR1 and DR5, but no such evidence in ischaemic heart disease.",These results suggest that there is no HLA association with idiopathic dilated cardiomyopathy or ischaemic heart disease.,0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0,0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
24_1,24,These data suggest that variation in class II HLA alleles could be a genetic factor involved in the susceptibility to IDC of the Mexican Mestizo population.,"In the IDC group, the frequency of human leukocyte antigen DR4 was similar to that reported in the normal population.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 1 0 1 1 0 1 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 1 0 0 0 0 1 0 0 1 1 0 1 1 1 1
24_2,24,"The results suggest that genetic factors play a role in the pathogenesis of dilated cardiomyopathy, and that since DR4 is frequently associated with auto-immune manifestations, a modified immune response is possible in dilated cardiomyopathy.",These results suggest that there is no HLA association with idiopathic dilated cardiomyopathy or ischaemic heart disease.,0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0,0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 1
24_4,24,"In conclusion, our data suggest that the variation in class II HLA alleles could be a genetic factor involved in the susceptibility to primary DCM in the Tunisian population.","In the IDC group, the frequency of human leukocyte antigen DR4 was similar to that reported in the normal population.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 1 0 1 1 0 1 0 0 0 1 1 0 0 0 1 0 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 1 0 0 0 0 1 0 0 1 1 1 1 1 1 1
24_7,24,These results suggest that HLA-DR4 antigen may be a genetic marker for susceptibility to dilated cardiomyopathy.,These results suggest that there is no HLA association with idiopathic dilated cardiomyopathy or ischaemic heart disease.,0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0,0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0,0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1
24_8,24,"This study provides some support for the concept of the risk of developing end-stage heart failure due to dilated cardiomyopathy being associated with possession of HLA DR1 and DR5, but no such evidence in ischaemic heart disease.","In the IDC group, the frequency of human leukocyte antigen DR4 was similar to that reported in the normal population.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 1 1 0 0 0 1 1 1 1 1 1 0 0 0 0 0 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 0 0 1 1 1 1 0 0 0 0 0 0 0 1 1
24_9,24,"In the Spanish Mediterranean area, the presence of antigens B-15 and DQ3 would be associated with advanced DCM.",The lack of any HLA antigen association in Omanis would argue against the proposed HLA-linked autoimmune pathology of idiopathic dilated cardiomyopathy.,0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0,1 1 1 1 1 0 0 0 0 1 0 1 0 0 0 0 1 1,1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 1 1 1 0 1 1 0 0 0 0 0 1 1 1 0 1 1 1
24_10,24,"DR4 and DR5 antigens were significantly more frequent in DC patients than in a normal population control (400 blood donors), while DR3 was less frequent.","In the IDC group, the frequency of human leukocyte antigen DR4 was similar to that reported in the normal population.",0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 1 1 0 0 0 0 1 1 1 0 0 0 0 0 1 1 1 1 0 1 0 0 0,0 0 0 0 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0,0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
24_11,24,"However, they suggest that genetically determined immune response factors associated with HLA loci may play a role in pathogenesis in certain patients with IDC.",These results suggest that there is no HLA association with idiopathic dilated cardiomyopathy or ischaemic heart disease.,0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 1 0 0 0 1 0 0 0 0 0 1 1 1 1 1 1,0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
24_12,24,These data suggest that variation in class II HLA alleles could be a genetic factor involved in the susceptibility to IDC of the Mexican Mestizo population.,The lack of any HLA antigen association in Omanis would argue against the proposed HLA-linked autoimmune pathology of idiopathic dilated cardiomyopathy.,0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1,1 1 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 1 1 0 0 0 0 1 0 1 1 0 0 0 0
24_13,24,These data suggest that variation in class II HLA alleles could be a genetic factor involved in the susceptibility to IDC of the Mexican Mestizo population.,These results suggest that there is no HLA association with idiopathic dilated cardiomyopathy or ischaemic heart disease.,0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0,0 0 0 0 1 0 1 1 0 1 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 1,0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
24_14,24,"Disease susceptibility to DCM in the Japanese population, thus, may be controlled in part by a gene (or genes) in close linkage disequilibrium with DRB1*1401-DQB1*0503, DRB1*1101-DQB1*0301, and DQB1*0604-DPB1*0401 haplotypes, while the resistance to DCM may be associated with the DRB1*0901-DQB1*0303 haplotype.","In the IDC group, the frequency of human leukocyte antigen DR4 was similar to that reported in the normal population.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0,1 1 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0 1 1 0 0 1 0 0 0 0 0 0 0 1 1,0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1,1 1 1 1 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0
24_15,24,"In conclusion, our data suggest that the variation in class II HLA alleles could be a genetic factor involved in the susceptibility to primary DCM in the Tunisian population.",The lack of any HLA antigen association in Omanis would argue against the proposed HLA-linked autoimmune pathology of idiopathic dilated cardiomyopathy.,0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 1 0 1 1 0 1 0 0 0 1 1 0 0 0 1 1 1 0 1 1 1 1,0 1 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 1 0 1 0 0
24_16,24,"In conclusion, our data suggest that the variation in class II HLA alleles could be a genetic factor involved in the susceptibility to primary DCM in the Tunisian population.",These results suggest that there is no HLA association with idiopathic dilated cardiomyopathy or ischaemic heart disease.,0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1,0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
24_17,24,"In the Spanish Mediterranean area, the presence of antigens B-15 and DQ3 would be associated with advanced DCM.","In the IDC group, the frequency of human leukocyte antigen DR4 was similar to that reported in the normal population.",0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0,1 1 1 1 1 0 0 0 0 1 0 1 0 0 0 0 1 1,0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1,1 1 1 1 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0
24_18,24,"We conclude that HLA-DR4, -DR15, -DPB1*0601 alleles confers susceptibility to, while DPB1*0101 allele confers protection from IDC among individuals of northern Chinese Han nationality.","In the IDC group, the frequency of human leukocyte antigen DR4 was similar to that reported in the normal population.",0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 1 1 1 1 0 1 1 0 1 1 0 1 1 0 1 1 1 1 1 1 1,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 1 1 1 0 1 0 0 0 0 1 0 0 1 1 1 1 1 1 1
24_19,24,These results suggest that HLA-DR4 antigen may be a genetic marker for susceptibility to dilated cardiomyopathy.,The lack of any HLA antigen association in Omanis would argue against the proposed HLA-linked autoimmune pathology of idiopathic dilated cardiomyopathy.,0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0,0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0,0 1 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 1 1 0 0 0 0
